

December 14, 2018

BSE Limited Floor 25, P. J. Towers Dalal Street, Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051

Dear Sirs,

Sub.: Intimation of Investor Meetings (Non-Deal Roadshow) during December, 17 and 18, 2018

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting investors/ analysts in Mumbai, India on December 17 and 18, 2018 as part of a Non-Deal Roadshow. We enclose details of investor/ analyst meetings scheduled for the same.

The schedule may undergo change due to exigencies on the part of Investors/ Analysts/ Company.

We also enclose the presentation to be used during the meetings.

This is for your kind information and records.

Thanking you,

Yours faithfully, For Jubilant Life Sciences Limited

Rajiv Shah Company Secretary

Encl.: as above

A Jubilant Bhartia Company



Jubilant Life Sciences Limited 1-A, Sector 16-A, Noida-201 301, UP, India Tel:+91 120 4361000 Fax:+91 120 4234895-96 www.jubl.com Regd Office: Bhartiagram, Gajraula Distt. Amroha - 244 223, UP, India CIN : L24116UP1978PLC004624

Investor/ Analyst meeting scheduled on December 17 and 18, 2018

Meeting Date	Type of Meeting	Name of fund/firm	Location
Monday, December 17, 2018	1 on 1	 Exide Life Insurance SBI Life Insurance Tata AIA Life Insurance IDBI Federal Life Insurance 	Mumbai
Tuesday, December 18, 2018	1 on 1	 ICICI Prudential Asset Management Reliance Capital Mirae Asset GI Aditya Birla Sun Life Insurance 	Mumbai





Jubilant Life Sciences Limited

Investor Presentation December 2018

Disclaimer

Important Disclaimer

This presentation (the "Presentation", or the "document") has been prepared by Jubilant Life Sciences Limited (the "Company") for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for use by the recipient only. The Presentation shall not, in whole or in part, be disclosed without prior written consent of the Company. This Presentation must not be copied, reproduced, distributed, or otherwise disclosed or passed on to others, in whole or in part, by any means, in any form under any circumstances whatsoever at any time hereafter. The recipient agrees to keep confidential any information contained herein and any other written or oral information otherwise made available in connection with the Company. In furnishing this document, neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, undertake any obligation to provide to the recipient (a) access to any additional information or to update this document, or (b) to correct any inaccuracies therein which may or may not become apparent.

This Presentation may contain statements about events and expectations that may be "forward-looking", including statements relating to future status, events, prospects or circumstances, including but not limited to statements about plans and objectives, outlook, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from these forward-looking statements due to number of risks and uncertainties, including future changes or developments in the Company's business, its competitive environment, its ability to implement its strategies and initiatives, respond to industry changes and the political, economic, regulatory and social conditions in India. The Company may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

This Presentation does not constitute a prospectus, offering circular or offering memorandum or an offer invitation or a solicitation of any offer to purchase or sell, any securities of the Company, and should not be considered or construed in any manner whatsoever as a recommendation that any person should subscribe for or purchase any of Company's securities. None of the projections, expectations, estimates or prospects in this Presentation should be construed as a forecast implying any indicative assurance or guarantee of future performance, nor that the assumptions on which such future projections, expectations, estimates, or prospects have been prepared are complete or comprehensive.

This Presentation utilizes information which has not been independently verified (including by opinion, anecdote and speculation) and which has been sourced from a variety of public sources and third parties. Neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, makes any representation or warranty (expressly or impliedly) as to the accuracy, adequacy or completeness of this document or its contents or of any other oral or written information furnished or made available. The Company disclaim to the extent possible by law, all responsibility in relation to this Presentation.

This Presentation, is not a recommendation to invest, is not an investment advice, and, is prepared to provide background information for investors in relation to the Company. This Presentation does not purport to contain all information investors may require to evaluate an investment in the Company. In preparing the Presentation, the Company have not taken into account the particular investment objectives, financial situation or particular needs of investors. Before making an investment decision, an investor should independently consider whether an investment in the Company is appropriate in light of its particular investment needs, objectives and financial circumstances. An investor should conduct its own independent investigations, due diligence and analysis of the potential benefits and risks of any investment in the Company. An investor should seek professional advice, including tax advice before making an investment decision.

The distribution of this Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients are required to inform themselves of, and comply with, all restrictions or prohibitions in such jurisdictions. Neither the Company nor any other person shall have any liability to any person in relation to the distribution or possession of this document or copies thereof in or from any jurisdiction where the distribution of such a document is prohibited or requires special authorisation or any regulatory consent or approval. By accepting this document the recipient has agreed, upon request, to return promptly all material received from the Company without retaining any copies.


By accepting this Presentation, the recipient agrees that this Presentation is strictly confidential and shall not be copied, published, distributed or transmitted to any person, in whole or in part, by any means, in any form under any circumstances whatsoever and that the recipient has further agreed, upon request, to return promptly all material received from the Company without retaining any copies. The recipient further represents and warrants that it is lawfully able to receive this Presentation under the laws of the jurisdiction in which it is located and / or any other applicable laws, and that it will not reproduce, publish, disclose, redistribute or transmit this Presentation.

NOTES

- 1. The numbers for the quarter have been reclassified and regrouped wherever necessary
- 2. Closing Exchange Rate for USD 1 at Rs. 66.25 as on March 31'16, Rs. 64.85 as on March 31'17, Rs 65.28 as on Sep 30, 2017, Rs. 65.17 as on March 31'18, and Rs 72.49 as on September 30, 2018
- 3. The Exchange fluctuation on long term forex loans in Indian books have been amortized over the tenure of the loan period as recommended under Indian Accounting Standards
- 4. Financial numbers upto FY 2015 are as per erstwhile Indian Generally Accepted Accounting Principles (I-GAAP), whereas for FY 2016 onwards, it is as per Indian Accounting Standards (Ind-AS)



Jubilant Life Sciences Overview




- USD 1.2 billion integrated global pharmaceuticals and life sciences company
- Strong position in Specialty Pharmaceuticals radiopharmaceuticals, allergy therapy products and CMO of Sterile Injectables & Non-Sterile products
- 6 USFDA approved manufacturing facilities including 4 in North America and 2 in India; 5 state-of-the-art LSI manufacturing facilities in India
- > Expertise in chemistry and manufacturing spanning over four decades of experience
- Employs ~7,600 people globally, including around 2,200 in North America and more than 500 dedicated to R&D







Evolution of Jubilant Pharma



Continued Focus on Specialty Pharmaceuticals – Radiopharmaceuticals, Contract Manufacturing and Allergy Therapy Products



Radiopharmaceuticals Business


Industry Overview ⁽¹⁾	 Radiopharmaceuticals Industry in North America is US\$2.4bn, expected to grow at CAGR of 6.2% to reach US\$3.5bn by 2023 Oncology and cardiology diagnosis accounted for 69.4% of the industry in 2017 Increase of cardiovascular, cancerous and neurological diseases are likely to drive molecular imaging procedures
Business Overview	 Specializes in cardiology, pulmonology, oncology and endocrinology as well as bone, brain and renal imaging Supplies 14 diagnostic and therapeutic radiopharmaceutical products to 18 countries <u>#3 radiopharmaceutical manufacturer</u> in nuclear medicine industry in the US based on revenue⁽¹⁾ Customers include 3rd party commercial radiopharmacy networks, our radiopharmacies, hospitals, standalone imaging centers and cardiologists Long-term contracts in place in the US USFDA approved manufacturing facility at Kirkland, Montreal
Products	 MAA for lung perfusion imaging (100% market share⁽¹⁾) DraxImage® DTPA for lung ventilation and renal imaging (100% market share⁽¹⁾) HICON® Sodium Iodine-131 solution for thyroid disease and thyroid cancer management (One of the only three manufacturers of I-131 (Thyroid) globally⁽¹⁾) RUBY® Rubidium Rb-82 Generator and RUBY® Rubidium Elution System (505 (b)(2)products) for myocardial perfusion imaging with PET DraxImage® Exametazime (505 (b)(2)product) for intra-abdominal infection and inflammatory bowel disease Planning to file NDA for I-131 mIBG (currently undergoing Phase II clinical trials in US) and 505(b)(2) for 4 other products
Strategy	 Achieve market leadership in the nuclear medicine industry Increase market share of RUBY-FILL® Generator and RUBY Elution System[™] - cardiac PET imaging Leverage leadership in existing products Expand product portfolio through launch of niche and differentiated products

(1) According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry 6

Market Size of Industry in North America

Radiopharmacy Business

- # 2 commercial radiopharmacy network in the US, operated under the "Triad Isotope" brand \geq
 - Facilities also include three operational cyclotrons
- Multi-year agreements with GPOs in place




Build the nation's premier centralised radiopharmacy network

- > Optimizing coverage of radiopharmacy network through further additions and improvements or consolidation
- Establish new distribution channels through collaboration and contractual arrangements with strategic Strategy partners
 - Geographic expansion in US and Canada by increasing brand recognition among hospital networks.




According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry

Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products






Allergy Therapy Business



Solid Dosage Formulations Business

≻	Global generics pharmaceutical industry stands at US\$111bn
	and is expected to grow at CAGR of 5.2% to reach US\$136bn
	by 2023

- It is estimated that there will be USD72.5 billion worth of small molecule drugs will have patent expiry from 2018 -22
 - Pharmerging market has seen strong growth both in volume (6.2%) and value (4.1%) in the recent past (2011-2016)- driven by preference for branded generics coupled with increase in out-of-pocket spend



- > 53 commercialized generic sound dosage formulations products across the US, Europe, Canada, Australia and the rest of the world⁽²⁾
 - ➢ 96 ANDA filings in the US of which 35 are pending⁽²⁾
 - \blacktriangleright We are one of the market leaders in select key products in the US⁽¹⁾
 - > Benefit from backward integration into API business supported by in-house R&D facilities
 - Manufacturing facility at Salisbury, US (USFDA) and Roorkee, India (USFDA, UKMHRA, PMDA Japan, ANVISA Brazil and MCC South Africa)
- #1 player in 3 products with over 35% share in each of the three products
- Amongst top 3 players in another 2 products
 - Amongst top 5 players in another 2 products

> Aim is to be the first to enter and last to exit using our chemistry and R&D capabilities and manufacturing expertise to drive growth

- > Focus on investment in R&D in order to increase our ANDA filings and approvals
- Focus on cost leadership with increased integration of in-house APIs
 - > Expand business into emerging markets by leveraging existing US filings
 - Increasing solid dosage formulations capacity at Roorkee facility
- (1) Source: Frost & Sullivan Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immunotherapy Industry and the Global and US Generic Pharmaceutical Industry

(2) As of September 30, 2018

Business

Overview

Products

Strategy

(3) Only includes prescription drugs



API Business

						<u>Global Ma</u>	rket Size : Synth	etic API	
						CA	GR (2018-22): 6.7%	6	
	≻	Clobal Synthetic ADI market	is US\$115bn in 2018 and is expected to grow at a		115	123	131	129	149
Industry		CAGR of 6.7% from 2018 to 2	이 가슴에 가슴	Î	48	51	53	46	62
Overview	۶	53% of outsourced API mark	ne se se la la sense de la	(nd\$SU)	67	72	78	83	87
					2018E	2019F	2020F Captive Ou	2021F utsourced	2022F
Business	> >	~80% of commercialized por ~60% of API sales are to regu	tfolio is in lifestyle driven therapeutic areas such as	is CVS	, CNS, anti-ir	nfective and n	on-communica	ble diseases	
Overview		Sartans continue to be a key		RIS M	exico and Br	azil ANVISA co	ertifications) ⁽²⁾		
Overview	>	Sartans continue to be a key	focus area	RIS M	exico and Br	azil ANVISA co		Global Marke	t Share ⁽¹⁾
Overview	>	Sartans continue to be a key API facility at Nanjangud, Kar	rocus area rnataka (USFDA, PMDA Japan, KFDA Korea, COFEPF	RIS M	Product	azil ANVISA c			t Share ⁽¹⁾
Overview Products ⁽¹⁾	>	Sartans continue to be a key API facility at Nanjangud, Kar Product	focus area rnataka (USFDA, PMDA Japan, KFDA Korea, COFEPF Jubilant Global Market Share ⁽¹⁾	RIS M	Product Meclizine			20%	t Share ⁽¹⁾
	>	Sartans continue to be a key API facility at Nanjangud, Kan Product Risperidone	rnataka (USFDA, PMDA Japan, KFDA Korea, COFEP Jubilant Global Market Share ⁽¹⁾ c.33%	RIS M	Product Meclizine Citalopram			20% 18%	t Share ⁽¹⁾
	>	Sartans continue to be a key API facility at Nanjangud, Kar Product Risperidone Oxcarbazepine	rnataka (USFDA, PMDA Japan, KFDA Korea, COFEP Jubilant Global Market Share ⁽¹⁾ c.33% c.30%	RIS M	Product Meclizine			20%	t Share ⁽¹⁾
	>	Sartans continue to be a key API facility at Nanjangud, Kar Product Risperidone Oxcarbazepine Carbamazepine	rnataka (USFDA, PMDA Japan, KFDA Korea, COFEP Jubilant Global Market Share ⁽¹⁾ c.33% c.30% 20%	RIS M	Product Meclizine Citalopram			20% 18%	t Share ⁽¹⁾
		Sartans continue to be a key API facility at Nanjangud, Kau Product Risperidone Oxcarbazepine Carbamazepine Pinaverium Continue to be a preferred s	rnataka (USFDA, PMDA Japan, KFDA Korea, COFEP Jubilant Global Market Share ⁽¹⁾ c.33% c.30% 20%		Product Meclizine Citalopram Donepezil			20% 18%	t Share ⁽¹⁾
		Sartans continue to be a key API facility at Nanjangud, Kar Product Risperidone Oxcarbazepine Carbamazepine Pinaverium Continue to be a preferred s Focus on product selection, r	rnataka (USFDA, PMDA Japan, KFDA Korea, COFEP Jubilant Global Market Share ⁽¹⁾ c.33% c.30% 20% 20% upplier to our customers	e of e	Product Meclizine Citalopram Donepezil	icts	Jubilant	20% 18% 16%	
Products ⁽¹⁾		Sartans continue to be a key API facility at Nanjangud, Kar Product Risperidone Oxcarbazepine Carbamazepine Pinaverium Continue to be a preferred s Focus on product selection, f Well differentiated strategy sustainable growth	rnataka (USFDA, PMDA Japan, KFDA Korea, COFEP Jubilant Global Market Share ⁽¹⁾ c.33% c.30% 20% upplier to our customers new product launches and increasing market share	e of ex	Product Meclizine Citalopram Donepezil	icts ighly capable	Jubilant team with a pro	20% 18% 16% oven track rec	








Specialty Intermediates & Nutritional Products

- Global specialty chemicals market is USD 1.1 billion in 2018 and is expected to grow at 5.4% to reach USD 1.2 billion in 2022.
- Global nutrition market is USD 570 billion in 2018, majorly dominated by Animal Feed Market (80%)



- Specialty Intermediates business comprises of Advance intermediates with product offerings such as Pyridines, Picolines, Cyanopyridines, Piperidine and their value added derivatives known as Fine Ingredients and Crop Science Ingredients
 - > Nutritional products business comprises of Vitamins, Animal Nutrition & Human Nutrition offering Vitamin B3, Vitamin B4 and Specialty Products
- Business Overview > Economies of scale and extensive backward and forward integration across the pyridine value chain drives cost competitiveness and secure supply chain.
 - > Exports account for over 60% of the business revenue
 - Strong customer base, end-to-end market offerings and market play in growth segments
 - > Product offerings service Pharmaceutical, Agrochemical, Personal Care, Healthcare, Nutrition (Human & Animal) & Other Life Science industries

	Key Product	Jubilant Global Market Share	Key Product	Jubilant India Market Share
Products	Pyridines ¹	21%	Vitamin B₄ (India)	64%
	Vitamin B ₃ ²	17%		

- Leverage integrated value chain to ensure cost advantages and higher margins
 - > Capacity expansion through regular debottlenecking & process intensification to meet incremental market demand

Strategy > Drive growth through new product launches thereby expanding product portfolio; Increase in customer alliances to defend market share and internal asset optimization

> Strategic product expansion to cater wide ranging agro applications; Focus on R&D oriented new products and CDMO for innovators



(1) - Merchant Sales Share

Industry

Overview

Source: IMS Database; Trade Datebase, Alltech Feed Survey, Euro Monitor

Life Science Chemicals

			<u>Market Size (KT)</u> <u>Anhydride</u>		<u>Global</u>	Market Size (KT <u>Acetate</u>	<u>): Ethyl</u>
Industry Overview	 Global Acetic Anhydride market is 585 KT in 2018 and is expected to grow at 4.2% to reach 662KT in 2022 Global Ethyl Acetate market is 2046 KT in 2018 and is expected to grow at 2% to reach 2156KT in 2022 	585 2018E	R (2018-2022): 4.2 610 2020F	662 2022F	2046 2018E	2082 2020F	2156 2022F
Business Overview	 Dominant player in domestic market for over 3 decades. High share in inte Only organized player in domestic market, supplies to all major customers Leading producer of Acetic Anhydride and Ethyl Acetate, which have appli Large scale ethanol producer; Ethanol used in Advanced intermediates an OMCs under GOIs Ethanol Blending Program Strategic location in India's sugarcane belt for cost efficient raw n One of the lowest cost manufacturers 	cations in Phar d Life science c	ma, Agro, Drug hemicals busin			ers of Ethanol	to

				Global Acetic Anhydride	Global Ethyl Acetate
	Key Product	Jubilant Global Market Share ⁽¹⁾	Jubilant India Market Share ⁽¹⁾	<u>(585KT) - 2018E</u>	<u>(2046KT) - 2018E</u>
(1)	Acetic Anhydride	16%	67%	94	123
Products ⁽¹⁾	Ethyl Acetate	6%	35%		Jubilant
	Ethanol		4 th largest supplier in the EBP program	491	1923 Share

- Capacity / Product / Geographic Expansion
 - > Continued capacity investment Acetic Anhydride capacity expansion underway with commissioning expected by Q4 FY19; annual revenue potential of ~Rs 400 Crore
 - > To capture the growing demand for acetic anhydride both in the domestic and in international markets
 - Acetic acid capacity expansion underway to further strengthen position in the global Acetic Anhydride market
 - Expansion of exports \geq
 - > Expansion in geographies such as Europe and South East Asia to drive growth in the business
- > Leverage integration and continuous improvement in manufacturing processes to drive cost efficiencies
- Leverage global sales and distribution network and reliable customer base \geq

Strategy





Jubilant Life Sciences – Key Strengths & Strategies



Jubilant Life Sciences Key Strengths



1 Leading Market Positions Across Business Lines, with High Barriers To Entry For Specialty Pharmaceuticals


		Highlights		Entry Barriers
	Radio pharmaceuticals	 #3 radiopharmaceuticals manufacturer in the US ⁽¹⁾⁽²⁾ #2 commercial radiopharmacy network in the US ⁽¹⁾⁽³⁾ Specialists in lung, thyroid, bone and cardiac imaging products 100% market share in the US in MAA and DTPA ⁽¹⁾ One of the only three manufacturers of I-131 globally ⁽¹⁾ Received two 505(b)(2) approvals for RUBYFILL[®] and DraxImage[®] Exametazime 	✓ Capital intensive na	y and licensing requirements ture of the business with commercial radiopharmacy business
Specialty Pharmac euticals	CMO of Sterile Injectables and Non Sterile Products	 ✓ Serves 7 out of the top 20 pharmaceuticals companies globally based on revenue⁽¹⁾ ✓ Deep and long-term relationships with our top 10 customers ✓ At least 10 years of business relationships with 6 of our top 10 customers⁽⁴⁾ 	for sterile injectable Proximity to custom	ners required to develop products, obtain
	Allergy Therapy Products	 One of the top #3 players in the allergenic extract market in the US⁽¹⁾ Product range of 200+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices Sole producer and supplier of venom products in the US⁽¹⁾ 	 ✓ Biotechnology prod require an NDA ✓ Niche US allergen e 	lucts with grandfather status; new products xtract market
Generics & APIs	Solid Dosage Formulations	 53 products across the, US, Europe, Canada, Australia and the rest of the world⁽⁴⁾ #1 player in 3 products with over 35% share in each of the three products Amongst top 3 players in another 2 products Amongst top 5 players in another 2 products) 	APIs	 One of the market leaders in the US for several key API products⁽¹⁾ Oxcarbazepine (global market share at c.30%) Carbamazepine (global market share at c.20%) and others
LSI	Speciality Intermediates and Nutritional Products	 Global leadership position in Pyridines & derivatives Second largest producer globally in Vitamin B3 Leader in 11 fine ingredients products 	Life Science Chemicals	 Globally top 2 in Acetic Anhydride (Merchant Sales) Globally #7 in Ethyl Acetate #4 Ethanol supplier in the GOI EBP program

(1) According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry; (2) As of 2017 revenue; (3) As of September 2017; (4) As of September 30, 2018

JUBILANT PHARMA

2 Global Competitive Edge Due to Low Cost and Vertical Integration


Vertical integration across the value chain enables cost competitive advantage resulting in higher margins



LIFESCIENCES


De-risked Business Model With Diverse Sources of Revenue

- Presence in niche Specialty businesses that have high barriers to entry
- ✓ Diverse end-use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries
- ✓ Presence across geographic locations enables the company to capture different market segments



Strong Pipeline of Products With Deep R&D Capabilities

- Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma
- Strong R&D support with a dedicated workforce of more than 500 R&D professionals
- 39 commercial APIs, 93 US DMFs filed




- Broad product portfolio of over 70 products driven by R&D capabilities and Chemistry expertise
- Strong R&D led product pipeline of 37 products, planned to be launched over the next 3-5 years
- Expertise in a large number of chemical processes; highly equipped laboratories with advanced equipments and analytical facilities
- Over 70 scientists in the LSI business
- 4 R&D centers Gajraula, Noida, Ambernath & Bharuch
- 143 patents filed till FY18

Life Science Ingredients (LSI) – Product Pipeline (FY19 – FY24)

LSI Businesses	Current Products (#)	Product Pipeline (#)
Life Science Chemicals	6	7
Specialty Ingredients	69	27
Nutritional Products	2	3
Total	77	37




5 High-Quality, World-Class, Low Cost Manufacturing Footprint



LIFESCIENCES

Experienced Management team with high standards of corporate governance




LIFE SCIENCES

24.7%

Demonstrated Financial Track Record with Strong Revenue Growth and

Attractive Profitability Profile




- Revenue increased at a CAGR of 9.1% over FY16-18 and EBITDA increased at 29.5% over the same period
- Increase in revenue and EBITDA attributable to increasing share of high margin Pharmaceuticals segment
 - Pharma margins at 25.8% in FY18 and 28.2% in H1'FY19 including Triad
 - Specialty Pharmaceuticals margin at 29.5% in H1'FY19 as against 37.6% in H1'FY18
 - Generics & API margin at 25.3% in H1'FY19 vs. 12.7% in H1'FY18
- Net Income up at a CAGR of 22.2% during FY16-FY18
- Net Debt / EBITDA down to 1.76x as on 30 Sep 2018 from 3.32x as on March 31, 2016



1. Reported EBITDA is after Corporate Expenses

Rs. Crs



3. Others Segment includes the Drug Discovery Solutions and India Branded Businesses

Growth Strategies and Plans

markets

Continue to strengthen leadership positions in key business segments > Radiopharmaceuticals: Achieve market leadership by leveraging leadership in existing products and expanding our product portfolio through the launch of niche and differentiated products **CMO**: Strengthen industry position through "first time right" customer service and identifying new customer targets for \geq ampoules, semi-solids and non-sterile liquids > Allergy: Continue to drive growth and profitability through our strong customer commitment to be the partner-of-choice in the US allergy market and leveraging the strong brand recognition of the "HollisterStier" brand > Formulations: Focus on cost leadership with increased integration in our portfolio mix and of in-house APIs and continue to expand our business into emerging markets by leveraging our existing US filings. **APIs:** Focused on product selection and cost optimization, to continue to be a preferred supplier to our customers Life Science Chemicals \triangleright Acetyls: Expand our market share globally of Acetic Anhydride by expanding capacities and maximize Ethyl Acetate profitability through customer and market prioritization Ethanol: Expand our presence and market share of Ethanol to OMCs in domestic market **Specialty Intermediates** \geq Retain top 2 global position in Pyridine & Picolines business New products development and launch to improve ROCE of FI & CSI business Expand CDMO business offering products from cGMP facilities to global Pharma Innovator customers Nutritional Products \geq Retain top 2 global position in Vitamin B3 with focus on feed, human nutrition and personal care industries; Expand Niacin . business also Expand & Retain ledership position in Vit B4 (Choline Chloride) in domestic market. Expand Animal and Human Nutrition product portfolio Be closer to the customer to provide high quality products and services 2 > Current Platform: Approximately 70% of our assets are in North America which account for 80% total revenue from operations (for FY18) **Targets**: Leverage the insights gained from successfully bringing products in North American market to launch products in other



Growth Strategies and Plans



- Manufacturing capacity and capabilities to further strengthen the radiopharmaceutical portfolio focused on the North American market
- Manufacturing sites in India to support Generics & APIs business





Appendix



Jubilant Life Science Q2/H1'19 – Financial Snapshot

Particulars	Q2 FY18	Q2 FY19	YoY Growth	H1 FY18	H1 FY19	YoY Growth	FY18
	(Rs	Crs)	(%)	(Rs Crs)		(%)	(Rs Crs)
Total Revenue from Operations (Net of Excise)	1642	2269	38%	3198	4348	36%	7518
Pharmaceuticals	855	1326	55%	1665	2507	51%	3995
Specialty Pharmaceuticals	531	908	71%	1000	1724	72%	2639
Generics & APIs	324	418	29%	665	783	18%	1357
Life Science Ingredients	738	887	20%	1438	1734	21%	3328
Others (incl. Drug Disc. and India Branded Pharma)	49	57	15%	94	107	14%	194
Total Expenditure	1336	1819	36%	2594	3460	33%	5999
Other Income	7	4	(46%)	14	13	(4%)	40
EBITDA from Operations	346	478	38%	707	931	32%	1657
Pharmaceuticals	218	364	67%	480	707	47%	1035
Specialty Pharmaceuticals	180	238	33%	395	508	29%	898
Generics & APIs	39	126	225%	85	198	134%	137
Life Science Ingredients	131	109	-17%	239	218	(9%)	632
Others (incl. Drug Disc. and India Branded Pharma)	(3)	4	-	(12)	6	-	(10)
Corporate (Expenses)/Income	(14)	(24)	-	(31)	(30)	-	(69)
Total	332	454	37%	677	901	33%	1588
One time expenses	19	0	-100%	19	0	(100%)	(30)
Reported EBITDA	313	454	45%	658	901	37%	1558
Depreciation and Amortization	79	89	13%	151	177	17%	415
Finance Cost	66	63	-5%	135	135	1%	284
Profit before Tax	168	302	80%	371	588	58%	859
Tax Expenses (Net)	43	92	116%	102	178	74%	225
Minority Interest	(3)	(1)	-	(6)	(3)	-	(8)
Net Profit After Tax and Minority Interest	128	210	64%	275	413	50%	643
Earnings Per Share - Face Value Re. 1 (Rs.)	8.23	13.50	64%	17.67	26.50	50%	41.25
	(5	%)	(bps)	(*	%)	(bps)	%
BITDA Margins from Operations	21.1%	21.0%	(5)	22.1%	21.4%	(69)	22.0
Pharmaceuticals	25.5%	27.5%	195	28.8%	28.2%	(61)	25.8
Life Science Ingredients	17.7%	12.3%	-545	16.6%	12.6%	(402)	19.0
Others (incl. Drug Disc. and India Branded Pharma)	-6.0%	7.4%	1,338	-12.4%	5.6%	1793	(5.4)
eported EBITDA Margin	19.1%	20.0%	93	20.6%	20.7%	16	20.7
et Margins	7.8%	9.3%	146	8.6%	9.5%	88	8.6



Debt Profile

Particulars	31/03/18	30/06/18	30/09/18
Foreign Currency Loans	(\$ Mn)	(\$ Mn)	(\$ Mn)
Standalone	9	9	0
Subsidiaries	358	358	363
Total	367	367	363
Rupee Loans	(Rs. Crs)	(Rs. Crs)	(Rs. Crs)
Standalone	1,007	1,081	1,238
Subsidiaries	79	62	86
Total	1,086	1,142	1,324
Gross Debt	(Rs. Crs)	(Rs. Crs)	(Rs. Crs)
Standalone	1,066	1,142	1,238
Subsidiaries	2,414	2,514	2,715
Total	3,480	3,657	3,953
Cash & Equivalent	249	329	523
Net Debt (before Fx Adjustment)	3,231	3,327	3,430
Change in debt on account of Fx rate difference from 31-March, 2018		-121	-265
Net Debt (After Fx Adjustment)	3,231	3,206	3,164
Reduction in net debt from March 2018, adjusted for Exchange difference		-25	-67
Closing Exchange Rate (USD/Rs.)	65.17	68.47	72.49

- Net debt at Rs. 3,164 Crore compared to Rs. 3,231 Crore on 31-March-2018 on constant currency basis
 Debt reduction of Rs. 108 Crore as compared with 31-March-2018
- Average blended interest rate for Q2'FY19 at 6.15% pa Re loans @ 8.42%, \$ loans @ 4.83%
- Stock Settlement Instrument (IFC) of US\$ 62.67 Million as a mandatory conversion option at IPO of Jubilant Pharma Limited



Our Vision & Promise

OUR VISION

To acquire and maintain global leadership position in chosen areas of businesses
To continuously create new opportunities for growth in our strategic businesses
To be among the top 10 most admired companies to work for
To continuously achieve a return on invested capital of at least 10 points higher than the cost of capital

OUR PROMISE *Caring, Sharing, Growing*

We will, with utmost care for the environment and society, continue to enhance value for our customers by providing innovative products and economically efficient solutions; and for our stakeholders through growth, cost effectiveness and wise investment of resources

Visit Us: Web Site: <u>www.jubl.com</u> Jubilant Life Sciences Limited, 1-A, Sector 16-A, NOIDA- 201301 UP, India

For Investors:

Ravi Agrawal Ph: +91-120-436 1002 E-mail: ravi.agrawal@jubl.com Vineet V Mayer Ph: +91-120-436 1021 E-mail: Vineet.mayer@jubl.com

